在晚期胰腺癌试验中,AIM ImmunoTech与Imfinzi组合的Ampligen药物显示出有前途,结果积极,耐受性强. AIM ImmunoTech's Ampligen drug in combo with Imfinzi shows promise in late-stage pancreatic cancer trial with positive results and tolerability.

AIM ImmunoTech已宣布其药物Ampligen与AstraZeneca的Imfinzi用于晚期胰腺癌的试验第1b/2阶段的初步结果大有希望。 AIM ImmunoTech has announced promising preliminary results from a Phase 1b/2 trial of its drug Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer. 治疗是良好的,没有注意到任何严重的副作用。 The therapy was well-tolerated, with no severe side effects noted. 值得注意的是,最初一组的3名病人中有2名达到了6个月的稳定性评估。 Notably, two of three patients in the initial group reached the six-month stability assessment. AIM ImmunoTech专门治疗癌症、免疫障碍和病毒疾病。 AIM ImmunoTech specializes in treatments for cancer, immune disorders, and viral diseases.